Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach

Shen, Ying‐Chun; Hsu, Chiun; Chen, Li-Tzong; Ченг, Чиа-Чи; Hu, Fu‐Chang; Cheng, Ann‐Lii

doi:10.1016/j.jhep.2009.12.041

Cited by 124 publications

(96 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Basic model-fitting techniques for variable selection, assessment of goodness-of-fit, and regression diagnostics were used to assure the quality of analysis results, as described before [28,29]. The meta-analysis and metaregression were done using the Cochrane Review Manager (RevMan) software, version 4.2 (Oxford, UK), the SAS statistical software (version 9.1.3, SAS Institute Inc., Cary, NC, USA), and the R statistical software version 2.6.1 (The R Project for Statistical Computing, http://www.r-project.…”

Section: Discussionmentioning

confidence: 99%

Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression

et al. 2012

Self Cite

View full text Add to dashboard Cite

Background The standard of chemotherapy regimens for advanced or metastatic gastric cancer and the clinical outcome were heterogeneous in Asian versus non-Asian countries. This study aimed to explore predictors of safety and efficacy of chemotherapy for patients with advanced or metastatic gastric cancer. Methods Treatment group-based meta-analysis and metaregression were performed to analyze results of randomized trials published since 2005 for advanced or metastatic gastric cancer patients who received systemic chemotherapy as first-line treatment. Data were extracted and synthesized according to the Cochrane guidelines. Results Twenty-five trials (8 Asian, 17 Western or international) with 56 treatment groups were analyzed.Asian trials reported a lower percentage of gastroesophageal junctional carcinoma, higher percentage of diffusetype histology, and more frequent use of second-line chemotherapy. Meta-analysis revealed significant heterogeneity both in treatment safety (grade 3-4 neutropenia and diarrhea) and efficacy [6-month progression-free survival (PFS) and 1-year overall survival (OS)]. Meta-regression analyses indicate that Asian trials are associated with an 8.2% lower incidence of grade 3-4 neutropenia and 2.1% lower incidence of grade 3-4 diarrhea. A lower percentage of patients with gastroesophageal junction carcinoma and the use of combination regimens predicted better PFS. The use of second-line chemotherapy predicts better 1-year OS, which will increase by 10% for every 10% increase in patients who received second-line chemotherapy. Conclusion Geographic region (Asian vs. non-Asian) is an independent predictor of safety in systemic therapy for gastric cancer.C. Hsu and Y.-C. Shen contributed equally to this work.Electronic supplementary material The online version of this article

show abstract

Section: Discussionmentioning

confidence: 99%

Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression

et al. 2012

Self Cite

View full text Add to dashboard Cite

show abstract

“…SVR was achieved in 13 (38%), 13 Table 2. Deaths due to hepatic failure caused by bile duct injury following RFA were included: one patient in cohort 3 with B-HCC and two patients in cohort 3 with C-HCC.…”

Section: E102 T Minami Et Al Hepatology Research 2015; 45: E99-e107mentioning

confidence: 99%

“…It has been reported that nucleoside/nucleotide analogs (NA) in hepatitis Brelated HCC (B-HCC) and interferon (IFN)-based therapy in hepatitis C-related HCC (C-HCC) had beneficial effects in terms of preventing recurrence and preserving liver function. [12][13][14] However, these trials enrolled only selected patients with specific conditions. It is not well documented whether the prognosis outside of clinical trials actually improved following radical percutaneous therapy.…”

Section: Introductionmentioning

confidence: 99%

Comparison of improved prognosis between hepatitis B‐ and hepatitis C‐related hepatocellular carcinoma

Minami

Tateishi

Shiina

et al. 2015

Hepatology Research

View full text Add to dashboard Cite

Aim: Treatment strategies for hepatocellular carcinoma (HCC) have been advanced. The aim of this study was to compare the change of the prognosis between hepatitis B-related HCC (B-HCC) and hepatitis C-related HCC (C-HCC) in the last two decades. Results: Two (11%), 24 (49%) and 80 (82%) B-HCC patients received nucleoside/nucleotide analogs during the follow-up period in cohorts 1-3, respectively. Among them 1, 18 and 62 patients achieved viral remission, respectively. Thirty-four (18%), 35 (8%) and 84 (14%) C-HCC patients received interferon therapy, respectively. The 5-year B-HCC (P < 0.001) survival rates were 52.6%, 61.1% and 81.6% for cohorts 1-3, respectively. However, the survival rates were 55.6%, 58.8% and 61.1% for C-HCC (P = 0.12), respectively. The B-HCC prognosis improved dramatically (P < 0.001) over time, whereas the prognosis of C-HCC improved moderately (P = 0.01). Methods: Conclusion:The prognosis of B-HCC has improved dramatically over time, whereas that of C-HCC has improved moderately.

show abstract

“…No effective therapy to reduce the risk of HCC recurrence is currently available (6), and systemic chemotherapy, hepatic-artery chemotherapy and chemoembolization have little effect (7,8). Other treatments, such as immunotherapy and interferon therapy, may improve overall survival and recurrence-free survival (9)(10)(11)(12). However, more studies are required before they can be recommended a part of the routine clinical practice.…”

Section: Introductionmentioning

confidence: 99%

Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence

Liao

Zheng

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Sorafenib is the standard systemic treatment for patients with advanced hepatocellular carcinoma (HCC); however, its therapeutic value in patients with HCC following resection remains controversial. The current retrospective study was undertaken to assess the effects of sorafenib treatment following surgical resection in patients with advanced HCC disease who were at a high risk for recurrence. Between July 2010 and July 2013, a consecutive cohort of 42 patients with advanced HCC and at a high risk of recurrence (i.e., those with portal vein tumor thrombosis, adjacent organ involvement or tumor rupture) who underwent resection were analyzed. The patients were categorized into the sorafenib group (n=14) or the best supportive care (BSC) group (n=28). Although the histological grade, Barcelona Clinic Liver Cancer Stage, tumor size, nodule number and proportion of patients with high serum α-fetoprotein levels were comparable between the sorafenib and BSC groups, those receiving sorafenib following resection had significantly longer disease-free survival (DFS) of 5.2 months [95% confidence interval (CI), 1.2-9.2 months] compared with the BSC group [1.8 months (95% CI, 0.6-3.0 months)]. No differences in overall survival were noted between the groups. Furthermore, no drug-related adverse events resulted in discontinuation of sorafenib therapy. Univariate log-rank analysis revealed that sorafenib treatment (P=0.002) and treatment prior to resection (P=0.012) were significantly associated with longer DFS; however, sorafenib therapy (P= 0.027) and tumor size (P= 0.028) were associated with longer DFS by multivariate analysis. Furthermore, sorafenib was well-tolerated and improved DFS in patients with advanced HCC who underwent hepatic resection. Thus, tumor resection followed by sorafenib therapy may represent an effective therapeutic strategy for patients with advanced HCC. This possibility should be confirmed in larger, multicenter studies.

show abstract

Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach

Cited by 124 publications

References 31 publications

Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression

Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression

Comparison of improved prognosis between hepatitis B‐ and hepatitis C‐related hepatocellular carcinoma

Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence

Contact Info

Product

Resources

About